Cell/Gene Tx channel feed

Cadre of gene-edit­ing biotechs ral­ly against al­ter­ing DNA that could af­fect fu­ture gen­er­a­tions

6 years ago

Biotech tar­get­ing rare heart mu­ta­tion with gene ther­a­py scores $11M in Se­ries A haul

6 years ago
Financing
Startups

Plug­ging in the last piece to its gene ther­a­py puz­zle, AskBio ac­quires Scot­tish syn­thet­ic pro­mot­er com­pa­ny

6 years ago
Deals

Ques­tions pile up for No­var­tis as sen­a­tors call on FDA to take ac­tion

6 years ago
FDA+

Bay­er is go­ing all in on next-gen stem cell biotech Blue­Rock, buy­ing out Ver­sant and founders for $600M

6 years ago
Deals

Part pro­ce­dure, part drug: Robert Ang joins Sid­dhartha Mukher­jee in pi­o­neer­ing a new type of cell en­gi­neer­ing

6 years ago
People
Startups

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

6 years ago
People

PACT Phar­ma says it's per­fect­ed the tech to se­lect neoanti­gens for per­son­al­ized ther­a­py — now on­to the clin­ic

6 years ago
Discovery

Keen to stay out front in cell ther­a­py, Gilead­'s Kite builds its own vi­ral vec­tor man­u­fac­tur­ing op­er­a­tions

6 years ago

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

6 years ago
People

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

6 years ago
R&D

Su­per­charg­ing CAR-T with can­cer vac­cine, MIT team spot­lights some new tech un­der­pin­ning Dar­rell Irvine's start­up

6 years ago
Discovery

Fresh out of Eli Lil­ly, Christi Shaw sur­faces as Daniel O'­Day's new CEO at CAR-T pi­o­neer Kite

6 years ago
People

Bil­lions on the line: Bio­Marin bus­tles past en­thused ri­val, plan­ning to launch world’s first he­mo­phil­ia A gene ther­a­py

6 years ago

The chief sci­en­tist at Ger­man/US biotech hy­brid Im­mat­ics is mov­ing to the helm. Here's his to-do list

6 years ago
People
R&D

Sang­amo/Pfiz­er are catch­ing up to Bio­Marin and Spark with a gene ther­a­py for he­mo­phil­ia A — can they leapfrog ahead?

6 years ago
R&D

Bay­er, Ver­sant back a $250M cell ther­a­py start­up on a quest to cre­ate off-the-shelf im­muno-on­col­o­gy ther­a­pies

6 years ago
Financing

Beef­ing up its new gene ther­a­py unit, Catal­ent inks $18M deal to snap up No­vavax fa­cil­i­ties

6 years ago
Outsourcing

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

6 years ago
Financing
Startups

Gene ther­a­py biotech sees its stock rock­et high­er on promis­ing re­sults for rare cas­es of but­ter­fly dis­ease

6 years ago
R&D

Sanofi Gen­zyme deserts gene ther­a­py de­vel­op­er Voy­ager Ther­a­peu­tics

6 years ago
Deals

Gene ther­a­py R&D deals turn red hot as Big Phar­ma steps up to play

6 years ago
Deals

Cue the M&A chat­ter: UniQure is scout­ing for a buy­out deal as gene ther­a­py field siz­zles — re­port

6 years ago
Deals

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

6 years ago
Pharma
First page Previous page 50515253545556 Next page Last page
A service from the Financial Times